LOCATION
Venture Café Cambridge
1 Broadway,5th Floor
Cambridge, MA 02142

DATE
April 25, 2019

TIME
3:00 – 8:30 PM

RSVP
HERE

ABOUT THIS EVENT

BIO Connect 2019

Save the date for Venture Cafe’s BIO Connect mini-conference, taking place on April 25th, 2019. Our annual mini-conference will feature the latest business, technology, and regulatory developments in drugs and therapeutics. Join experts, innovators, and investors for a dialogue about funding and successes in the sector. Click here to register!

OUR SPONSORS

If you’re interested in sponsoring Bio Connect contact Ruth Saunders

OUR PARTNERS

PARTICIPATING COMPANIES

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

AGENDA AT A GLANCE

3:00 PM – 5:00 PM   OFFICE HOURS

4:15 PM – 5:00 PM   PRESENTATION

5:15 PM – 6:15 PM   PANEL: FUNDING LIFE SCIENCES

5:30 PM – 8:00 PM   BIOTECH DEMOS

6:00 PM – 6:45 PM   FLASH TALKS, ROUND I

6:30 PM – 7:30 PM    SHARK TANK

7:00 PM – 7:45 PM   FLASH TALKS, ROUND II

 

 


Blank
OFFICE HOURS (3:00 PM - 5:00 PM)

 

Special Office Hour Appointments (Bio Connect Only)

 

Stephanie Lustgarten
Takeda

Stephanie Lustgarten, Verastem Oncology

Stephanie has nearly 15 years of experience in clinical development in the life sciences/biotechnology/pharmaceutical industry with a focus in oncology. Additionally, she has experience in phase I through phase III clinical trials and has lead global regulatory submissions from a clinical data sciences perspective, including New Drug Applications (NDA) and Marketing Authorization Application (MAA). Stephanie received her Ph.D. in biostatistics from Boston University and has worked at small, mid-size and larger life sciences organizations within the Boston area.

BOOK NOW

 

 
Rouzbeh Taghizadeh Auxocell

Rouzbeh Taghizadeh
Auxocell

Rouzbeh Taghizadeh, Co-Founder & Chief Scientific Officer, Auxocell

Dr. Rouzbeh R. Taghizadeh has dedicated more than 20 years to bringing stem cell-based therapies to clinical practice. His expertise in adult stem cells, primarily human hematopoietic and mesenchymal stem cells—the regenerative cells involved in successful bone marrow and umbilical cord blood transplantations—uniquely positions him to approach science and business with the same keen powers of insight that have consistently reaped success surmounting scientific and medical barriers in the field.

BOOK NOW

 

 
PRESENTATION: THE CONVERGENCE OF DIGITAL HEALTH AND DISEASE (4:15 PM - 5:00 PM)

PRESENTATION: THE CONVERGENCE OF DIGITAL HEALTH AND DISEASE (4:15 PM – 5:00 PM)

How digital tech will affect how inclusion in therapy options will occur in the future and why it’s important to get involved. Highlights importance of point of care for patients who can’t afford advanced therapies in hospitals. Descriptions of what some of the access barriers for minorities are for advanced therapy options. Highlight disease trends on wider diverse populations and how the process of engagement works now vs what can be achieved

(Room: Havana)

 

Anil Achyuta, Director of External Innovation L’Oreal

Reginald Swift, Founder / CEO
RUBIX Life Sciences

Reginald Swift, Founder / CEO, RUBIX Life Sciences

With a career that started in the aerospace & defense sector, being able to translate engineering, quality and transformational concepts happens to be a core competency that has been developed over the 14-year career. Navigating between Life Science, Nuclear, Aerospace & Defense & Robotics; he has developed novel technologies within his company of Rubix LS that are being highlighted in both the government and commercial sectors.

PANEL: FUNDING LIFE SCIENCES (5:15 PM – 6:15 PM)

PANEL: Funding Life Sciences (5:15 PM – 6:15 PM)

Industry experts and thought-leaders representing venture capital and entrepreneurship community will offer perspectives on the capital ecosystem from both sides of the table. Join us as Martha Farmer from North Shore InnoVentures leads a discussion on ways to fund life sciences from grants to venture investment.

(Room: Havana)

 

Anil Achyuta, Director of External Innovation L’Oreal

Martha Farmer, Founder
North Shore InnoVentures

Martha Farmer, Founder, North Shore InnoVentures

Dr. Martha C. Farmer, PhD – is the Founder of North Shore InnoVentures, a non-profit life sciences incubator in Beverly, MA. She serves on the Board of two companies, Atentiv and TSRL, on the SAB of Virtech Bio, and on the Board of Advisors of Endicott College, among others. She started her industry career at Baxter Healthcare. She earned a BS in zoology and a PhD in physiology from Duke University, did postdoctoral training at Johns Hopkins University and was a Medical Ethics Fellow at Harvard University. 30 publications; 3 patents.

Anil Achyuta, Director of External Innovation L’Oreal

Isaac B. Stoner, Co-Founder
Octagon Therapeutics

Isaac B. Stoner, Co-Founder, Octagon Therapeutics

Isaac currently serves as co-founder and Chief Operating Officer of Octagon Therapeutics, a drug discovery company targeting metabolic vulnerabilities in disease-causing cells. Isaac also serves as Advisor to KdT Ventures, a venture capital firm focused on the intersection of computational technologies with life science innovation. Prior to Octagon, Isaac was an early hire at several successful startups, including Firefly BioWorks and Ion Torrent, and spent time in venture capital.

Anil Achyuta, Director of External Innovation L’Oreal

Shaoyu Chang, Vice President
FC Capital

Shaoyu Chang, Vice President, FC Capital

Shaoyu is Vice President at FC Capital, a cross-border venture capital fund specializing in life sciences and healthcare investments. Shaoyu takes an active leadership role the full lifecycle of investment, from origination and evaluation to execution and management. Previously, Shaoyu served as Investment Manager for VI Ventures, a Hong Kong-based healthcare VC firm. Prior to that, Shaoyu was Director of Investor Research at Life Science Nation and Research Scholar at Duke University.

Anil Achyuta, Director of External Innovation L’Oreal

Rhie-young Lim, Founder,
Life Canvas Technologies

Rhie-young Lim, Founder, Life Canvas Technologies

Rhie-young Lim is the co-founder and VP of Operations at LifeCanvas Technologies Inc. where she oversees the company’s daily operations, marketing, global sales and strategy. Prior to joining LifeCanvas, Rhie drove marketing initiatives for MIT’s entrepreneurship education arm, and launched the institute’s first entrepreneurship bootcamp overseas in Seoul with the South Korean government. She also served as CNBC’s Seoul correspondent for 4 years doing live hits on the South Korean stock market.

Anil Achyuta, Director of External Innovation L’Oreal

Brian Gallagher, Partner
Abingworth

Brian Gallagher, Partner, Abingworth

Dr. Gallagher is a Partner at Abingworth since 2018. He has >20 years of investing, BD, operational and R&D experience. Previously he was a Partner at SR One since 2010. He was with Sirtris responsible for Corp Dev, operations and integration following the $720M acquisition by GSK (2008). He was with Alantos and played key roles in the R&D and BD activities prior to the $300M acquisition by Amgen (2007). He began his career in R&D at Eisai. He received his MS/PhD degrees in organic chemistry from Michigan and BS in chemistry from Massachusetts.

DEMOS (5:30 PM – 8:00 PM)

BIO CONNECT DEMOS (5:30 PM – 8:00 PM)

Venture Cafe demos are a great way to gain exposure through our online and offline channels. During our Bio Connect event, Venture Café will give a selection of the area’s start-ups, inventors and researchers an opportunity to showcase their work to the Boston community!

 

FLASH TALKS ROUND I (6:00 PM - 6:45 PM)

FLASH TALKS, ROUND I (6:00 PM – 6:45 PM)

These sessions are community-generated, lightning sessions comprised of 30 minutes of content and 15 minutes of networking for each session. Join these entrepreneurs to learn a variety of hard and soft skills and also hear their behind the scenes stories about innovative research or what takes to run a successful company.

 

 

Brian J. Malkin

Brian J. Malkin
Arent Fox LLP

Brian J. Malkin, Arent Fox LLP

“Regulatory developments in orphan drugs” (Location: Santa Clara Conference Room)

Brian is an attorney in Arent Fox’s FDA, Intellectual Property, and Health Care groups. Brian has more than 25 years of food and drug law practice and over 14 years of intellectual property law practice. In particular, his practice includes the interrelation between patent law and food and drug law. Brian’s regulatory experience includes all types of FDA-regulated products: drugs (including animal drugs), biologics, medical devices, foods and dietary supplements, tobacco products, and cosmetics.

 
Susan Stewart

Susan Stewart,
Kaleido Biosciences

Susan Stewart, Kaleido Biosciences

“Regulatory developments in orphan drugs” (Location: Santa Clara Conference Room)

Susan Stewart has served as Kaleido’s Senior Vice President, Regulatory Affairs & Quality since April 2018. Ms. Stewart has worked for more than 27 years in biopharmaceutical regulatory affairs, with significant experience devising innovative strategies for novel therapeutics, overseeing regulatory submissions at various stages of product development and leading interactions with global health authorities. Previously, she was SVP regulatory affairs, Genzyme Corporation, Tokai Pharmaceuticals, and TMI. She is principal at SRC.

 

 

Arantza Muriana, Biobide

Arantza Muriana, Biobide

Arantza Muriana, Biobide

“Alternative in vivo animal models for rare diseases”

“Regulatory developments in orphan drugs” (Location: Octave Conference Room)

Developing alternative in vivo models for orphan and rare diseases, is now easier thanks to Crispr-cas and other gene technologies. This way, many dieases that did not have an in vivo model for preclincial testing, and that in clinical trials had not many patients either can develop a more efficient drug discovery. Enhancing the R&D with in vivo models that resemble those rare diseases.

 
Seth rhoades

Seth Rhoades, Robur Health

Seth Rhoades, Robur Health

“The Lean (Bio)Startup: Is It Possible?” (Location: Presto Conference Room)

The popularized notion of “garage startups” typically applies to tech, given low capital requirements, low barriers to entry, and fast development cycles. These concepts are now increasingly applicable to biotech, given the open access to large datasets, advances in compute infrastructures and algorithms, lower costs of outsourced experiments, and new nucleic acid editing technologies. Join me as I discuss data, AI, and drug discovery in a new era of biotech.

 
SHARK TANK (6:30 PM - 7:30 PM)

SHARK TANK (6:30 PM – 7:30 PM)

BIO Connect is hosting its annual Life Sciences Shark Tank. This was a huge success in 2017 and 2018. Five life science entrepreneurs will pitch a panel of investors. It is a great platform to pitch, meet and build relationships with investors in the Life Sciences sector.

 

 
Aisha Nabiyeva, Supply Chain R&D Retail Business Services

Avi Spier 
Novartis

Avi Spier, Novartis

Avi Spier is Director or NIBR BD&L, Search and Evaluation with Novartis.
In 2001, Dr. Spier co-founded La Jolla based Allon Therapeutics, Inc. and led the peptide therapeutic neurodegenerative disease-focused company as its President and CEO through two financing rounds and up to its entry onto the Toronto Stock Exchange. In 2004, Dr. Spier joined the Genomics Institute of the Novartis Research Foundation (GNF), as its Director of Business Development. In 2012 Dr. Spier was appointed Director of BD&L in NIBR, with responsibility for search and evaluation activities for the Cardiovascular, Metabolic and Diabetes (CVM), Global Discovery Chemistry (GDC), Chemical Biology and Therapeutics (CBT), GNF Systems and the Microbiome organizations of NIBR. Dr. Spier was educated in Biological Sciences at Oxford University, received his Ph.D. in molecular neuroscience from Cambridge University at the MRC-Laboratory of Molecular Biology and trained as a postdoc at The Scripps Research Institute (TSRI), La Jolla, CA.

 
Aisha Nabiyeva, Supply Chain R&D Retail Business Services

Peter Fasse, Principal
Fish & Richardson P.C.

Peter Fasse, Principal, Fish & Richardson P.C.

Peter is an angel investor and patent attorney who supports clients ranging from start-ups to multi-nationals. Peter’s focus lies in the life sciences, healthcare, medical systems and green-tech to develop competitive worldwide patent portfolios, provide third-party patent risk analysis, patent opinions and client counseling. His current clients are involved in medical diagnostics and therapies, microfluidics, CRISPR, RNAi, cancer therapies, liquid biopsies, and medical software.

 
Aisha Nabiyeva, Supply Chain R&D Retail Business Services

Anh Ngo,
Ascentia Asset Management

Anh Ngo, Ascentia Asset Management

Dr. Ngo is an Instructor of Anaesthesia and Pain Medicine Fellow at Harvard Medical School, BIDMC. He received his BS, MBA, and MD from the University of California Irvine and completed his anesthesiology residency at the USC Keck School of Medicine. He has been involved with several companies, including a boutique investment firm and a medical group merger and acquisition exit valued in the mid-eight figure range. Anh is also a member of Mass Medical Angels (MA2) and part of a life sciences hedge fund, Ascentia Asset Management.

 
FLASH TALKS ROUND II (7:00 - 7:45 PM)

FLASH TALKS, ROUND II (7:00 – 7:45 PM)

These sessions are community-generated, lightning sessions comprised of 30 minutes of content and 15 minutes of networking for each session. Join these entrepreneurs to learn a variety of hard and soft skills and also hear their behind the scenes stories about innovative research or what takes to run a successful company.

 

Ryan kelly Abveris

Ryan kelly
Abveris

Ryan Kelly, Abveris

“Strategies For Therapeutic Antibody Discovery Against Tricky Targets” (Location: Presto Conference Room)

Biopharmaceutical drug discovery scientists are in a race to develop therapeutic antibodies against increasingly difficult antigens, like multi-pass transmembrane proteins. This discussion will review a series of strategies to develop antibodies against cell surface targets, and some known strengths and weaknesses for each approach.

 

Bryanna Allison
Life Science Nation

Bryanna Allison, Business Development Mgr, Life Science Nation

“Navigating a Life Science Conference in Boston” (Location: Octave Conference Room)

Bryanna Allison is an international business development manager for Life Science Nation, the parent company of the RESI Conference. At Life Science Nation she serves as a liaison for early stage entrepreneurs and investors. Bryanna will discuss how to successfully navigate a Life Science Conference. Primarily, the power of partnering, and how to prepare for your next investor meeting.

 

SPEAKERS

Martha Farmer

North Shore InnoVentures

Rhie-young Lim

Life Canvas Technologies

Isaac B. Stoner

Octagon Therapeutics

Shaoyu Chang

FC Capital

Brian Gallagher

Abingworth

Avi Spier

Novartis

Anh Ngo

Ascentia Asset Management

Peter Fasse

Fish & Richardson P.C.

Reginald Swift

RUBIX Life Sciences

Arantza Muriana

Biobide

Brian J. Malkin

Arent Fox LLP

Susan Stewart

Kaleido Biosciences

Seth Rhoades

Robur Health

Ryan Kelly

Abveris

Social Share Buttons and Icons powered by Ultimatelysocial